FAST-PATH will create faster tools to diagnose Prostate Cancer
A Marie Curie Industry-Academia Partnerships and Pathways funded programme.
Prostate cancer is the second most common form of cancer in men. Around 910,000 cases of prostate cancer were recorded in 2008, accounting for nearly 14% of all new cancer cases in men. In the same year, there were over 250,000 deaths from the disease and it is predicted that the number of cases will almost double to 1.7 million by 2030.
The FAST-PATH research programme will contribute significantly to our understanding of the mechanisms and pathology underlying prostate cancer. Above all, the results of our research in this area will ultimately benefit the cancer patients by refining the pathological process used in prostate cancer detection and management.
The FAST-PATH programme is a consortium of industrial and academic partners and was successfully awarded the European Marie Curie FP7 grant in October 2011. The overall funding amount is projected at just over €1.9 million.